X Xue1, Z Li2, M Zhao2. 1. Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China. 2. Key Lab of Medical Shock and Microcirculation Research of Guangdong Province, Department of Pathophysiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Abstract
OBJECTIVE: To construct a luciferase reporter gene vector carrying human nuclear factor of activated T cells 2 (NFATc2) gene promoter and examine the effects of metformin and lipopolysaccharide (LPS) on the transcriptional activity of NFATc2 gene. METHODS: The promoter sequence of human NFATc2 gene was acquired from UCSC website for PCR amplification. NFATc2 promoter fragment was inserted into pGL3-basic plasmid double cleaved with Kpn Ⅰ and Hind Ⅲ. The resultant recombinant plasmid pGL3-NFATC2-promoter was co-transfected with the internal reference plasmid pRL-TK in 293F cells, and luciferase activity in the cells was detected. Reporter gene vectors of human NFATc2 gene promoter with different fragment lengths were also constructed and assayed for luciferase activity. The changes in transcription activity of NFATc2 gene were assessed after treatment with different concentrations of metformin and LPS for 24 h. We also examined the effect of mutation in RUNX2-binding site in NFATC2 gene promoter on the regulatory effects of metformin and LPS on NFATc2 transcription. RESULTS: We successfully constructed pGL3-NFATc2-promoter plasmids carrying different lengths (2170 bp, 2077 bp, 1802 bp, 1651 bp, 1083 bp, 323 bp) of NFATc2 promoter sequences as verified by enzymatic digestion and sequencing. Transfection of 293F cells with the plasmid carrying a 1651 bp NFATc2 promoter (pGL3-1651 bp) resulted in the highest transcriptional activity of NFATc2 gene, and the luciferase activity was approximately 3.3 times that of pGL3-2170 bp (1.843 ± 0.146 vs 0.547 ± 0.085). Moderate (5 mmol/L) and high (10 mmol/L) concentrations of metformin significantly upregulated the transcriptional activity of pGL3-1651 bp by up to 2.5 and 3 folds, respectively. LPS at different doses also upregulated the transcriptional activity of pGL3-1651 bp by at least 1.6 folds. The mutation in the RUNX2 binding site on pGL3-1651 bp obviously reduced metformin- and LPS-induced enhancement of pGL3-1651bp transcription by 1.7 and 2 folds, respectively. CONCLUSION: pGL3-NFATc2-promoter can be transcribed and activated in 293F cells, and LPS and metformin can activate the transcription of pGL3- NFATc2-promoter in a RUNX2-dependent manner.
OBJECTIVE: To construct a luciferase reporter gene vector carrying human nuclear factor of activated T cells 2 (NFATc2) gene promoter and examine the effects of metformin and lipopolysaccharide (LPS) on the transcriptional activity of NFATc2 gene. METHODS: The promoter sequence of human NFATc2 gene was acquired from UCSC website for PCR amplification. NFATc2 promoter fragment was inserted into pGL3-basic plasmid double cleaved with Kpn Ⅰ and Hind Ⅲ. The resultant recombinant plasmid pGL3-NFATC2-promoter was co-transfected with the internal reference plasmid pRL-TK in 293F cells, and luciferase activity in the cells was detected. Reporter gene vectors of human NFATc2 gene promoter with different fragment lengths were also constructed and assayed for luciferase activity. The changes in transcription activity of NFATc2 gene were assessed after treatment with different concentrations of metformin and LPS for 24 h. We also examined the effect of mutation in RUNX2-binding site in NFATC2 gene promoter on the regulatory effects of metformin and LPS on NFATc2 transcription. RESULTS: We successfully constructed pGL3-NFATc2-promoter plasmids carrying different lengths (2170 bp, 2077 bp, 1802 bp, 1651 bp, 1083 bp, 323 bp) of NFATc2 promoter sequences as verified by enzymatic digestion and sequencing. Transfection of 293F cells with the plasmid carrying a 1651 bp NFATc2 promoter (pGL3-1651 bp) resulted in the highest transcriptional activity of NFATc2 gene, and the luciferase activity was approximately 3.3 times that of pGL3-2170 bp (1.843 ± 0.146 vs 0.547 ± 0.085). Moderate (5 mmol/L) and high (10 mmol/L) concentrations of metformin significantly upregulated the transcriptional activity of pGL3-1651 bp by up to 2.5 and 3 folds, respectively. LPS at different doses also upregulated the transcriptional activity of pGL3-1651 bp by at least 1.6 folds. The mutation in the RUNX2 binding site on pGL3-1651 bp obviously reduced metformin- and LPS-induced enhancement of pGL3-1651bp transcription by 1.7 and 2 folds, respectively. CONCLUSION: pGL3-NFATc2-promoter can be transcribed and activated in 293F cells, and LPS and metformin can activate the transcription of pGL3- NFATc2-promoter in a RUNX2-dependent manner.
Authors: Einav Shoshan; Russell R Braeuer; Takafumi Kamiya; Aaron K Mobley; Li Huang; Mayra E Vasquez; Guermarie Velazquez-Torres; Nitin Chakravarti; Cristina Ivan; Victor Prieto; Gabriel J Villares; Menashe Bar-Eli Journal: Cancer Res Date: 2016-03-24 Impact factor: 12.701
Authors: Shane P Simonett; Sunyoung Shin; Jacob A Herring; Rhonda Bacher; Linsin A Smith; Chenyang Dong; Mary E Rabaglia; Donnie S Stapleton; Kathryn L Schueler; Jeea Choi; Matthew N Bernstein; Daniel R Turkewitz; Carlos Perez-Cervantes; Jason Spaeth; Roland Stein; Jeffery S Tessem; Christina Kendziorski; Sündüz Keleş; Ivan P Moskowitz; Mark P Keller; Alan D Attie Journal: J Clin Invest Date: 2021-11-01 Impact factor: 14.808
Authors: Li Ni; Satadru K Lahiri; Jiali Nie; Xiaolu Pan; Issam Abu-Taha; Julia O Reynolds; Hannah M Campbell; Haihao Wang; Markus Kamler; Wilhelm Schmitz; Frank Ulrich Müller; Na Li; Xiang Wei; Dao Wen Wang; Dobromir Dobrev; Xander H T Wehrens Journal: Cardiovasc Res Date: 2022-10-21 Impact factor: 13.081
Authors: Matthew B Greenblatt; Susan Y Ritter; John Wright; Kelly Tsang; Dorothy Hu; Laurie H Glimcher; Antonios O Aliprantis Journal: Proc Natl Acad Sci U S A Date: 2013-11-18 Impact factor: 11.205
Authors: Izabela P Klaska; Elizabeth Muckersie; Cristina Martin-Granados; Maria Christofi; John V Forrester Journal: Immunology Date: 2016-12-18 Impact factor: 7.397
Authors: Paul M Jordan; Nico Andreas; Marco Groth; Philine Wegner; Franziska Weber; Ute Jäger; Claudia Küchler; Oliver Werz; Edgar Serfling; Thomas Kamradt; Anne Dudeck; Sebastian Drube Journal: Immunology Date: 2021-06-17 Impact factor: 7.397